NEW YORK (GenomeWeb News) – SDIX reported after the close of the market on Wednesday that its second-quarter revenues fell 10 percent year over year.
The Newark, Del.-based company said that for the three months ended June 30, revenues totaled $5.5 million, down from $6.1 million a year ago. The drop-off was primarily related to the timing of in vitro diagnostic sales, it said, as well as continued weakness in the biopharmaceutical market.